Search

Your search keyword '"Lin, AB"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Lin, AB" Remove constraint Author: "Lin, AB"
45 results on '"Lin, AB"'

Search Results

1. Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancer

5. Correction.

6. APPaRENT 3: Asthma Patients' and Physicians' Perspectives on the Burden and Management of Asthma in Seven Countries.

7. Meigs syndrome presenting with recurrent unilateral pleural effusion.

8. Changes in Lipid Profiles with the Progression of Pregnancy in Black Women.

9. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.

10. Dietary fish oil enriched in very-long-chain polyunsaturated fatty acid reduces cardiometabolic risk factors and improves retinal function.

11. Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia.

12. Satisfaction and tolerability using virtual reality (VR) as adjunctive treatment during flexible bronchoscopy: a randomized control trial.

13. Untargeted Analysis of Lipids Containing Very Long Chain Fatty Acids in Retina and Retinal Tight Junctions.

14. A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.

15. Therapeutic high affinity T cell receptor targeting a KRAS G12D cancer neoantigen.

16. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

17. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.

18. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.

19. A rare presentation of isolated carpal bone tuberculous osteomyelitis mimicking gouty arthritis.

20. Silicone pneumonitis after gluteal filler: a case report and literature review.

21. A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.

22. Cluster Analysis Evaluating PM2.5, Occupation Risk and Mode of Transportation as Surrogates for Air-pollution and the Impact on Lung Cancer Diagnosis and 1-Year Mortality.

23. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

24. UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT.

25. Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

27. Treatment patterns and health care resource use in patients receiving multiple lines of therapy for metastatic squamous cell carcinoma of the head and neck in the United Kingdom.

28. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

29. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.

30. Suture Granuloma 14 Years Following Partial Thyroidectomy Masquerading as Tuberculosis af The Sinus Tract.

31. Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair.

32. Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes.

33. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients.

34. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

35. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

36. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

37. Analysis of the immune response of human dendritic cells to Mycobacterium tuberculosis by quantitative proteomics.

38. Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice.

39. Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.

40. Medical therapy for glaucoma: what to add after a prostaglandin analogs?

41. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.

42. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.

43. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.

44. Mesenchymal stem cells in regenerative medicine for musculoskeletal diseases: bench, bedside, and industry.

45. Disseminated tuberculosis masquerading primary myelodysplastic syndrome.

Catalog

Books, media, physical & digital resources